BUZZ-Ventyx jumps as oral drug reduces heart disease risk markers in mid-stage trial
I'm PortAI, I can summarize articles.
Shares of Ventyx Biosciences surged 70% to $6.58 in premarket trading after the company announced that its oral drug VTX3232 significantly reduced key inflammation markers associated with heart disease in a mid-stage trial. The drug lowered hsCRP levels by approximately 80% within the first week and also reduced IL-6 levels below the cardiovascular risk threshold. Additionally, a combination with Novo Nordisk’s semaglutide further decreased inflammation markers, although it did not enhance weight loss. Year-to-date, VTYX shares are up about 76%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments